Novartis AG Sponsored ADR (NVS)
Novartis: The Buy Thesis Is Back (Rating Upgrade)
Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine, the performance of its oncology franchise was remarkably strong. So, sales of Pluvicto, a medication used to treat PSMA-positive metastatic castration-resistant prostate cancer, were $651 million in Q2, up 43.4% year-on-year.
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well
Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.
Novartis Q2 Earnings Call Highlights
Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto.
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Novartis CEO Vas Narasimhan says 'no change of plans'
Novartis chief executive officer Vas Narasimhan said on Tuesday he plans to stick around for the Swiss drugmaker's next phase of growth, ahead of a series of high-stakes trial data expected for the company in the second half of the year.
Novartis Returns to Growth on Sales Momentum From Key Drugs
Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.
Novartis faces drug pipeline test with valuation premium in focus
Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss drugmaker's premium valuation.
Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.
Gear Up for Novartis (NVS) Q2 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon
Novartis continues to favor in-licensing and bolt-on acquisitions. The Myricx Bio acquisition expands Novartis' ADC pipeline with novel NMTi payloads, but commercial impact is several years away. Avidity's del-brax and Ionis's pelacarsen, both late-stage assets, offer multibillion-dollar peak sales potential with pivotal data expected in the second half of the year.
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition
NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.
